SUMATRIPTAN SUCCINATE (AUTOINJECTOR) Drug Patent Profile

Which patents cover Sumatriptan Succinate (autoinjector), and when can generic versions of Sumatriptan Succinate (autoinjector) launch?

Sumatriptan Succinate (autoinjector) is a drug marketed by Onesource Specialty and is included in one NDA.

The generic ingredient in SUMATRIPTAN SUCCINATE (AUTOINJECTOR) is sumatriptan succinate. There is one drug master file entry for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sumatriptan Succinate (autoinjector)

A generic version of SUMATRIPTAN SUCCINATE (AUTOINJECTOR) was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for SUMATRIPTAN SUCCINATE (AUTOINJECTOR)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
DailyMed Link:	SUMATRIPTAN SUCCINATE (AUTOINJECTOR) at DailyMed

US Patents and Regulatory Information for SUMATRIPTAN SUCCINATE (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Onesource Specialty	SUMATRIPTAN SUCCINATE (AUTOINJECTOR)	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	090314-002	Jan 30, 2026	AB	RX	No	No

Sumatriptan Succinate Autoinjector Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 9, 2026

Sumatriptan succinate autoinjectors are mature, off-patent migraine products competing on price, device convenience, supply reliability, and payer access. The original Imitrex STATdose franchise has lost meaningful exclusivity, while lower-dose products such as Zembrace SymTouch retain commercial differentiation through device design and dosing rather than active-ingredient protection. Revenue growth is unlikely to come from molecule expansion. The principal financial outlook is stable-to-declining branded revenue, continued generic price pressure, and a smaller premium market for patients who need rapid, non-oral administration.

What is the current FDA status of sumatriptan succinate autoinjectors?

The FDA-approved active ingredient is sumatriptan succinate, a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine, with or without aura, in adults. Injection products generally deliver sumatriptan subcutaneously.

Product category	Typical dose	Delivery system	U.S. regulatory status
Imitrex injection and STATdose	6 mg/0.5 mL	Cartridge or autoinjector system	Approved, mature branded product
Generic sumatriptan injection	Usually 6 mg/0.5 mL	Vial, syringe, or device-compatible presentation	Approved through abbreviated applications
Zembrace SymTouch	3 mg/0.5 mL	Single-use autoinjector	Approved branded lower-dose product
Sumavel DosePro	6 mg/0.5 mL	Needle-free device	Historical product; commercial availability has been limited
Oral and nasal sumatriptan	Variable	Tablet, nasal spray, or powder	Separate dosage forms with separate regulatory records

The FDA label for Imitrex injection identifies 6 mg/0.5 mL as the standard adult dose, with a second dose permitted after at least one hour subject to a 12 mg daily maximum for the injection formulation (U.S. Food and Drug Administration [FDA], 2024a). Zembrace SymTouch uses a 3 mg dose and allows a second dose after at least one hour, with a maximum of 12 mg in 24 hours (FDA, 2024b).

The main regulatory distinction is not the active ingredient. It is the delivery system, dose strength, cartridge architecture, needle system, and usability profile.

When does sumatriptan autoinjector exclusivity expire?

Sumatriptan’s core U.S. exclusivity has expired. The molecule was introduced in the United States in the early 1990s, and generic versions have been available for many years.

Exclusivity timeline

Event	Approximate timing	Commercial effect
Original U.S. approval of Imitrex injection	1990s	Established the injectable sumatriptan market
Core compound and product patent protection	Expired by the late 2000s or early 2010s, depending on patent and jurisdiction	Enabled generic competition
Generic injectable sumatriptan approvals	2000s onward	Reduced active-ingredient pricing
Zembrace SymTouch approval	2018	Created a lower-dose, device-differentiated branded product
Zembrace clinical exclusivity period	Expired around 2021	Reduced regulatory barriers to competing applications
Current U.S. market	Mature generic and branded niche	Competition centers on price, device, and contracting

The original sumatriptan compound patent estate is no longer a meaningful barrier to generic entry. Any remaining commercial protection would have to arise from device patents, formulation claims, manufacturing know-how, trademarks, or contractual distribution arrangements.

What patents protect sumatriptan succinate autoinjectors?

The active ingredient is not the principal patent barrier. The relevant intellectual-property categories are device configuration, cartridge design, needle deployment, dose control, packaging, and manufacturing processes.

Active-ingredient patents

The early sumatriptan patent estate covered the chemical compound and pharmaceutical use. Those patents expired before the current market phase. Generic manufacturers therefore can compete with products containing the same active ingredient without licensing the original compound patent.

Formulation patents

Sumatriptan injection formulations are relatively simple compared with long-acting biologics or complex drug-device combinations. A typical formulation contains sumatriptan succinate in aqueous solution with excipients used for pH control and stability. Formulation claims may cover concentration, pH, excipient selection, or stability, but these claims have limited market power when alternative formulations can be developed.

Autoinjector and device patents

Device protection can remain commercially relevant after drug patents expire. Potentially protected elements include:

• Automated needle insertion and retraction.
• Cartridge puncture and fluid transfer.
• Dose-volume control.
• Activation force and two-step operation.
• Safety locks and needle shielding.
• Device geometry designed for self-administration.
• Packaging that preserves sterility and device integrity.

A device patent does not necessarily block a generic drug product in a vial or conventional syringe. It has greater impact when the reference product is a drug-device combination and the generic applicant seeks to copy the same delivery system.

Orange Book status

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity for approved drug products. For mature sumatriptan injection products, the commercial significance of Orange Book-listed active-ingredient patents is limited because the core patent estate has expired. Device-related rights may not produce the same type of Orange Book barrier as a listed drug patent and may instead be enforced through separate patent litigation or design-around analysis (FDA, 2024c).

How many patents cover sumatriptan autoinjectors?

There is no economically meaningful single patent count without defining the product, jurisdiction, assignee, and claim type. A practical freedom-to-operate review should separate:

1. Expired compound patents.
2. Expired or weak formulation patents.
3. Potentially active autoinjector patents.
4. Manufacturing and assembly patents.
5. Foreign-country rights.
6. Trademark and trade-dress rights.

For U.S. market entry, the key question is whether a proposed injector infringes an unexpired device claim. A generic applicant can reduce risk by using a different actuator, needle mechanism, cartridge interface, or safety architecture. The product can also enter first in a vial or prefilled syringe, although that approach sacrifices some convenience and branded-device differentiation.

Which companies compete in the sumatriptan autoinjector market?

Competition is fragmented across branded manufacturers, generic drug companies, contract manufacturers, and migraine-focused pharmaceutical companies.

Branded competition

The principal historical branded product is Imitrex injection, associated with GlaxoSmithKline’s original migraine franchise. The commercial brand remains recognized, but the product no longer has the pricing power associated with an actively protected medicine.

Zembrace SymTouch competes through a 3 mg autoinjector presentation. Its differentiation is based on dose flexibility and ease of administration rather than a new pharmacological mechanism.

Generic competition

Generic injectable sumatriptan suppliers compete through:

• Wholesale acquisition price.
• Pharmacy and hospital contracting.
• Product availability.
• Syringe or vial format.
• Packaging configuration.
• Ability to supply cartridges or device-compatible presentations.

The generic market is structurally more price-sensitive than the branded autoinjector market. A supplier with a reliable device platform may retain better margins than a supplier selling an undifferentiated vial, but the margin advantage is constrained by payer substitution and pharmacy benefit management.

Therapeutic competition

Sumatriptan autoinjectors compete with:

• Oral generic sumatriptan.
• Other injectable triptans, particularly injectable DHE products.
• Nasal triptans.
• CGRP receptor antagonists such as ubrogepant and rimegepant.
• Intranasal zavegepant.
• Preventive therapies that reduce attack frequency.
• Emergency-department-administered migraine treatments.

CGRP antagonists have expanded the non-vasoconstrictive treatment segment. Their higher prices create a reimbursement barrier, leaving injectable sumatriptan relevant for patients with severe, rapid-onset attacks or failed oral therapy.

What is the financial trajectory for sumatriptan succinate autoinjectors?

The financial trajectory is mature and bifurcated.

Branded revenue trajectory

Branded revenue has likely declined from the peak of the original Imitrex franchise because:

• The molecule is generic.
• Payers encourage substitution.
• Oral and nasal alternatives address many patients.
• New CGRP therapies compete for migraine spending.
• The autoinjector serves a narrower population than oral tablets.
• Large manufacturers do not generally report sumatriptan autoinjector revenue as a separate public segment.

The remaining branded opportunity is concentrated in patients who value rapid self-administration, cannot tolerate oral medication during an attack, or prefer a lower-dose device.

Generic revenue trajectory

Generic revenue is more resilient in volume but weaker in price. Unit demand can remain stable because migraine is a chronic episodic condition and sumatriptan is an established first-line acute therapy. Revenue per unit tends to decline as additional suppliers enter.

The financial model is therefore:

Driver	Direction	Effect
Patient volume	Stable to modestly rising	Supports unit demand
Price per dose	Downward	Compresses revenue
Branded device premium	Positive but limited	Protects selected patients
CGRP competition	Negative	Pressures higher-value patients
Supply reliability	Positive for established suppliers	Supports contracting
Manufacturing complexity	Higher than tablets	Limits some entrants
Payer substitution	Negative for brands	Accelerates generic conversion

Standalone financial figures for the autoinjector segment are generally not disclosed in public issuer filings. Reported company revenue usually combines multiple dosage forms, products, or therapeutic categories. Product-specific market-research estimates can differ materially based on whether they include all sumatriptan formulations, triptan therapies, or only injectable devices.

How strong is the patent estate for sumatriptan autoinjectors?

The patent estate is weak for the molecule and potentially moderate for a particular device implementation.

Patent-strength assessment

IP category	Current strength	Commercial assessment
Sumatriptan compound	Low	Expired
Basic injectable formulation	Low	Mature technology with design-around options
Branded autoinjector architecture	Moderate, product-specific	Can delay copying of a device
Manufacturing process	Low to moderate	Relevant if process claims are narrow and difficult to design around
Trademark and brand	Moderate	Supports recognition but not exclusivity
Distribution contracts	Short-term commercial value	Can affect access without blocking entry
Trade dress	Limited	Usually insufficient to sustain pharmaceutical exclusivity

The strongest barrier is likely operational rather than patent-based: development of a reliable sterile filling process, cartridge system, injection mechanism, and regulatory package.

What generic entry risks exist for sumatriptan autoinjectors?

Generic entry risk is high for conventional injectable presentations and moderate for closely copied autoinjectors.

Paragraph IV risk

A generic applicant may file an Abbreviated New Drug Application with a Paragraph IV certification if it believes an Orange Book-listed patent is invalid, unenforceable, or not infringed. For legacy sumatriptan injection products, the probability of a major Paragraph IV dispute is lower than for recently approved drugs because core patents have expired.

A device-specific challenge could still arise if:

• The reference product has an unexpired listed patent.
• The generic seeks the same proprietary device architecture.
• The reference sponsor asserts a device patent outside the main Orange Book pathway.
• The generic label or product design is alleged to induce infringement.

Launch scenarios

Scenario	Probability profile	Market effect
Vial or syringe generic entry	High	Rapid price erosion and broad substitution
Device-compatible generic entry	Moderate	Greater competitive pressure on branded autoinjectors
Authorized generic launch	Possible	Accelerates price competition while preserving sponsor channel control
Device patent litigation	Low to moderate	Could delay a close-copy injector
Branded niche persistence	High	Premium survives in selected patients

What patent litigation affects sumatriptan autoinjectors?

There is no widely recognized, current U.S. litigation campaign comparable to the major patent disputes surrounding protected CGRP drugs or biologic migraine therapies. Historical disputes involving sumatriptan have generally been more relevant to compound, formulation, or delivery technology than to a currently blocking autoinjector patent.

The litigation exposure is product-specific. A diligence review should examine:

• FDA Orange Book listings.
• USPTO assignment and maintenance records.
• Federal district court cases.
• International Trade Commission investigations.
• Abbreviated application litigation under the Hatch-Waxman Act.
• Device patent ownership and licensing chains.

How does sumatriptan autoinjector compare with newer migraine drugs?

Attribute	Sumatriptan autoinjector	CGRP antagonist	Nasal migraine therapy
Patent position	Mostly expired	Often active	Product-specific
Price	Low for generic	Higher	Intermediate to high
Onset and use case	Rapid, useful when oral therapy fails	Convenient, non-vasoconstrictive	Useful when oral route is unsuitable
Cardiovascular restrictions	Important	Generally less restrictive	Varies by product
Payer access	Strong for generics	Often prior authorization	Variable
Device differentiation	Important	Usually not injection-based	Spray-device dependent
Revenue growth potential	Limited	Higher for protected products	Moderate

Sumatriptan retains a cost and familiarity advantage. Newer therapies retain an exclusivity and tolerability advantage. The autoinjector occupies a narrow but defensible segment where route of administration matters.

What licensing deals and commercial partnerships matter?

The relevant commercial arrangements typically involve:

• Rights to branded sumatriptan products.
• Contract manufacturing for sterile injectable drug products.
• Autoinjector platform licensing.
• Device component supply.
• Authorized-generic distribution.
• Specialty-pharmacy and wholesaler contracts.

Because product-level agreements are not consistently disclosed, licensing value must be assessed through ownership of the NDA, device patents, manufacturing sites, and distribution rights. A deal involving the drug alone has limited strategic value unless it includes a differentiated injector, an established payer channel, or manufacturing capacity.

What geographic markets offer the strongest opportunity?

The United States is the most commercially structured market because of FDA approval, generic substitution, and established reimbursement channels. European markets also have mature sumatriptan use, but pricing is more heavily controlled and autoinjector adoption varies by country.

Potentially attractive markets share four conditions:

1. High migraine diagnosis and treatment rates.
2. Limited access to rapid non-oral therapies.
3. Reimbursement for self-injection devices.
4. Local manufacturing or distribution capability.

Emerging-market growth is more likely to come from tablets and low-cost injectables than from premium autoinjectors. Device costs, reimbursement limitations, and cold-chain or sterile manufacturing requirements can restrict uptake.

Key Takeaways

• Sumatriptan succinate autoinjectors are mature, off-patent products.
• The active ingredient does not provide meaningful current U.S. exclusivity.
• Device patents, manufacturing capability, and usability are more important than compound patents.
• Generic entry risk is high for vials and conventional syringes.
• Close-copy autoinjectors face greater device and regulatory complexity.
• Branded revenue is likely declining or stable at a niche level, while generic volume remains more durable.
• Imitrex has strong brand recognition but limited pricing power.
• Zembrace SymTouch differentiates through a 3 mg autoinjector presentation.
• CGRP antagonists are the main high-value therapeutic competitors.
• No major current patent litigation campaign is broadly associated with the legacy sumatriptan autoinjector market.
• The strongest commercial opportunity is operational: reliable sterile manufacturing, device usability, payer access, and supply continuity.

FAQs About Sumatriptan Succinate Autoinjector Patents and Market Value

Is sumatriptan autoinjector still patent protected?

The sumatriptan molecule and core injectable therapy are no longer protected by meaningful U.S. compound exclusivity. Product-specific device patents may still require review.

Can a generic company launch a sumatriptan autoinjector?

Yes. A generic company can pursue an abbreviated application, but it must address device performance, human-factor requirements, labeling, manufacturing, and any unexpired patent claims.

Is Zembrace SymTouch more valuable than generic sumatriptan injection?

It can command greater value in a narrow patient segment because of its 3 mg autoinjector design. Its premium is constrained by generic 6 mg injection products and alternative migraine therapies.

Does sumatriptan injection require Paragraph IV certification?

Only if the relevant reference product has an applicable Orange Book-listed patent. For mature sumatriptan products, the principal compound patents have expired, so Paragraph IV exposure is product-specific rather than automatic.

What is the main barrier to launching a competing sumatriptan autoinjector?

The main barrier is integrated drug-device development, including sterile filling, cartridge and injector reliability, human-factor validation, regulatory approval, and cost-effective manufacturing.

References

1. U.S. Food and Drug Administration. (2024a). Imitrex injection prescribing information.
2. U.S. Food and Drug Administration. (2024b). Zembrace SymTouch prescribing information.
3. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024d). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations.